Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2027 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients. Herantis is listed on the Nasdaq First North Growth Market Finland.
| Website | https://herantis.com/ |
| Ticker | HRTIS |
| Revenue | $1 million |
| Employees | 23 (14 on RocketReach) |
| Founded | 2008 |
| Address | 1 Bertel Jungin Aukio, Espoo, Uusimaa 02600, FI |
| Phone | +358 9 2221195 |
| Industry | Biotechnology Research, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Clinical Trials, Health Care, Pharmaceutical |
| Web Rank | 3 Million |
| Keywords | Herantis Pharma, Lymfactin®, Finland Pharmaceuticals Distributors, Oncology Importers In Finland, Cdnf |
| Competitors | Roche, Novartis, Sanofi, GSK, Bristol Myers Squibb, AbbVie, Amgen, Pfizer, Merck & Co., Inc., Regeneron +49 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Herantis Pharma Plc. employee's phone or email?
Herantis Pharma Plc. Questions
The Herantis Pharma Plc. annual revenue was $1 million in 2026.
Antti Vuolanto is the CEO of Herantis Pharma Plc..
14 people are employed at Herantis Pharma Plc..
Herantis Pharma Plc. is based in Espoo, Uusimaa.
The NAICS codes for Herantis Pharma Plc. are [32, 3254, 325, 32541].
The SIC codes for Herantis Pharma Plc. are [28, 283].
Top Herantis Pharma Plc. Employees
Related Companies
